Advances in Hematology / 2012 / Article / Tab 3

Review Article

Lenalidomide in Diffuse Large B-Cell Lymphoma

Table 3

Response to lenalidomide in patients with diffuse large B-cell lymphoma in first-line treatment.

Name of the protocolR2-CHOP [56]LR-CHOP21 [57]R2-CHOP [58]
Year of publication201120102011

Type of studyMonocentricMulticentric-IILMulticentric
PhasePhase IPhase I-IIPhase I-II
TreatmentLenalidomide and R-CHOP21Lenalidomide and R-CHOP21LenalidomideandR-CHOP21
 Dose of lenalidomide:15 to 25 mg/d, D1–105 to 20 mg/d, D1–145 to 25 mg/d, D1–14 
every 21 daysevery 21 daysevery 21 days
 No. of cycles666
 No. of patients
 with DLBCL
242127
 Recommended dose
 in function of DLT
25 mg15 mg25 mg
Toxicity
 HematologicGrade III-IVGrade III-IVGrade III-IV
  Anemia21%4%
  Neutropenia88%28%59%
  Thrombocytopenia29%10%30%
Grade IIIGrade IIIGrade I-IIGrade III
 Peripheral neurotoxicity8%14%48%0%
 Vascular thrombosis8%7%
Response
 ORR , (%)22 (87.5)16 (72)27 (100)
 CR , (%)18 (77)15 (71)20 (74)
 PR , (%)1 (5)7 (26)
 Stable disease , (%)
 Progression , (%)5 (21)5 (16)

R-CHOP: rituximab 375 mg/m2 D1, cyclophosphamide 750 mg/m2 D1, doxorubicin 50 mg/m2 D1, vincristine 1.4 mg/m2 D1 (capped at 2.0 mg) prednisone 50 mg/m2 D1–5.
DTL: dose limiting toxicity.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.